Gritstone bio will host a virtual key opinion leader event on Friday, August 2 at 9:00 AM ET featuring J. Randolph Hecht, MD, and Howard Brown who will discuss the unmet need and current treatment landscape for patients with metastatic microsatellite stable colorectal cancer. Gritstone management will also highlight the development of Gritstone’s personalized neoantigen vaccine program, GRANITE, as a potential treatment for immunologically “cold” tumors including MSS-CRC. Mature progression-free survival data from a randomized Phase 2 study of GRANITE in frontline MSS-CRC are expected in the third quarter of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRTS:
- Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
- Gritstone announces inducement grants under Nasdaq listing rule
- Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Levi & Korsinsky LLP Announces the Filing of a Securities Class Action on Behalf of Gritstone bio, Inc.(GRTS) Shareholders
- Gritstone bio to Participate in Upcoming Investor and Scientific Conferences